Filed - Glenmark

Licensing Strategy
Partner Selection
• Selection criteria : (a) drug development skills (b) experience in therapy area
(c) Marketing prowess (d) deal value (e) development program/speed to market
• Preference for before Phase IIA/PoC deal timing;
Sales $ Bn
$400
$300
$200
$100
Licensing Focus
US
EU
Jap
Retain rights: high
growth markets of
Asia, Africa,
Russia, Lat Am,
Australia
APPROACH TO LICENSING
• Retain use of clinical data generated
by partner
• Retain exclusive /
co- commercialization rights to
products for Asia, Africa, Australia,
Lat Am and Russia
• Register product upon US/EU
approval in these markets and launch
$0
0% 5% 10% 15% 20%
Annual Sales Growth
License out the leads to partners for the markets of North America, Europe and
Japan; retain exclusive / co-commercialization rights for rest of the world
7